tradmap

BCRX Biocryst Pharmaceuticals Inc

$10.10 -0.79%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Biocryst Pharmaceuticals Inc (BCRX) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $2.6 billion. Shares last traded at $10.10, 9.9% below their 52-week high. Over the past year the stock is up 21.8%. Net profit margin is -40.9%, below the peer median of 5.3%. Revenue grew 94.1% year over year.

Market Cap
$2.6B
Shares Out
255.5M
EPS (TTM)
$-5.47
P/E Ratio
P/S Ratio
2.74
P/B Ratio
Dividend / Share
Dividend Yield
52-Week High
$11.21
52-Week Low
$6.00
Volume
151,413
Avg Vol (3m)
285,642.206

Performance

1W
+2.33%
1M
+11.29%
3M
+19.24%
6M
+19.10%
YTD
+34.76%
1Y
+21.76%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
56.31
SMA (50)
$9.75
SMA (200)
$8.56
Price vs SMA50
+3.61%
Price vs SMA200
+18.01%
ATR (14)
$0.45

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$941M
Net Income
$-385M
Gross Margin
97.8%
Operating Margin
-33.3%
Net Margin
-40.9%
Return on Equity
84.7%
Return on Assets
-69.0%
Current Ratio
2.32
Debt / Equity
-0.87
Revenue Growth (YoY)
+94.1%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-2.59 2026-08-05
Q1 2026 $-2.98 2026-05-06
FY 2025 $1.21 2026-02-26
Q3 2025 $0.08 2025-11-04
Q2 2026 $0.02 2026-08-05
Q1 2026 $0.00 2026-05-06

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

BCRX vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
2.74 / 19.49 med
-86% discount
Net margin vs peers
-40.9% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.